NCT02338193 - Dapagliflozin and Metformin,Alone and in Combination, in Overweight/Obese Prior GDM Women | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 22, 2015

Primary Completion Date

February 13, 2019

Study Completion Date

March 13, 2019

Conditions

Diabetes Prevention in Women After GDM Who Are at High-risk

Interventions

DRUG

DAPA/MET XR

final dose- 5 mg dapagliflozin/1000 mg glucophage XR BID for 20-24 weeks

DRUG

DAPA

10 mg dapagliflozin QD for 20-24 weeks

DRUG

MET XR

1000 mg Metformin XR BID for 20-24 weeks

Trial Locations (1)

Woman's Hospital, Baton Rouge